63874-99-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-chlorophenyl)-1H-pyrazole-4-carbaldehyde is utilized as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with diverse therapeutic applications. Its unique structure allows for the creation of compounds with specific biological activities, enhancing the range of treatments available in the medical field.
Used in Agrochemical Development:
In the agrochemical industry, 1-(4-chlorophenyl)-1H-pyrazole-4-carbaldehyde serves as a crucial component in the synthesis of new agrochemicals. Its incorporation into these products can lead to the development of more effective and targeted pest control solutions, benefiting agricultural productivity and sustainability.
Used in Organic Synthesis:
As a versatile chemical compound, 1-(4-chlorophenyl)-1H-pyrazole-4-carbaldehyde is employed as a substrate in organic synthesis. Its reactivity and structural features enable the formation of a wide array of novel chemical compounds with various applications across different industries, including materials science, pharmaceuticals, and agrochemicals.
Used in Chemical Research and Development:
Due to its unique properties and structural attributes, 1-(4-chlorophenyl)-1H-pyrazole-4-carbaldehyde is a valuable compound in the field of chemical research and development. It is used to explore new chemical reactions, mechanisms, and pathways, contributing to the advancement of chemical knowledge and the discovery of innovative applications.

InChI:InChI=1/C10H7ClN2O/c11-9-1-3-10(4-2-9)13-6-8(7-14)5-12-13/h1-7H

Upstream product

• 25419-86-7 1-(4-chlorophenyl)-1H-pyrazole 
• 68-12-2 N,N-dimethyl-formamide 
• 108-90-7 chlorobenzene 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 1073-70-7 4-chlorophenylhydrazine hydrochloride 
• 100-97-0 hexamethylenetetramine 
• 1073-69-4 N-4-chlorophenylhydrazine 

Downstream Products

• 63875-00-3 1-(4-chloro-phenyl)-4-(4-trifluoromethyl-1⁽³⁾H-imidazol-2-yl)-1H-pyrazole 
• 1373836-36-2 2-(1-(p-chlorophenyl)pyrazol-4-yl)benzimidazole 
• 138907-80-9 1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid 
• 1410806-35-7 1-[1-(4-Chloro-phenyl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-ethanone 
• 1410806-73-3 2-chloro-1-[1-(4-chloro-phenyl)-1H-pyrazol-4-yl]-ethanone 
• 1283289-77-9 C₁₀H₆Cl₂N₂O 
• 1422960-52-8 (E)-1-(4-chlorophenyl)-4-(2-nitrovinyl)-1-phenyl-1H-pyrazole 
• 1612877-10-7 (E)-2-(2-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)vinyl)quinolin-8-ol 
• 1612877-19-6 C₂₂H₁₆ClN₃O₂ 
• 1449038-88-3 3-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methoxy)propyl 4-toluenesulfonate 
• 1449038-87-2 2-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methoxy)ethyl 4-toluenesulfonate 
• 1449038-86-1 3-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methoxy)propan-1-ol 
• 1449038-85-0 2-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methoxy)ethanol 
• 1449038-84-9 4-(allyloxymethyl)-1-(4-chlorophenyl)-1H-pyrazole 

Relevant academic research and scientific papers

Electrophotocatalytic SNAr Reactions of Unactivated Aryl Fluorides at Ambient Temperature and Without Base

The electrophotocatalytic SNAr reaction of unactivated aryl fluorides at ambient temperature without strong base is demonstrated.

Electrophotocatalysis with a Trisaminocyclopropenium Radical Dication

Visible-light photocatalysis and electrocatalysis are two powerful strategies for the promotion of chemical reactions. Here, these two modalities are combined in an electrophotocatalytic oxidation platform. This chemistry employs a trisaminocyclopropenium (TAC) ion catalyst, which is electrochemically oxidized to form a cyclopropenium radical dication intermediate. The radical dication undergoes photoexcitation with visible light to produce an excited-state species with oxidizing power (3.33 V vs. SCE) sufficient to oxidize benzene and halogenated benzenes via single-electron transfer (SET), resulting in C?H/N?H coupling with azoles. A rationale for the strongly oxidizing behavior of the photoexcited species is provided, while the stability of the catalyst is rationalized by a particular conformation of the cis-2,6-dimethylpiperidine moieties.

The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment

Piperazine is a promising scaffold for drug development due to its broad spectrum of biological activities. Based on this, the new piperazine-containing compound LQFM018 (2) [ethyl 4-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate] wa

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases

Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies associated with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies. When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacological effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation. These unwanted effects can be overcome by using partial A1R agonists. Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window. This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks. To circumvent solubility and formulation issues for neladenoson, a prodrug approach was pursued. The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved solubility and exposure after oral administration. Neladenoson bialanate hydrochloride is currently being evaluated in clinical trials for the treatment of heart failure.

PYRAZOLYL PYRIMIDINAMINE COMPOUND AND APPLICATION THEREOF

Disclosed are pyrazolyl pyrimidinamine compounds with structures as shown in Formula I: The definitions of each of the substituents can be seen in the description. The compounds of present invention have a broad spectrum of bactericidal, insecticidal and acaricidal activity, and have good control effect on downy mildew of cucumber, powdery mildew of wheat, corn rust, anthracnosis of cucumber and the like, and especially have better control effect on downy mildew of cucumber, powdery mildew of wheat and anthracnosis of cucumber. The compounds of present invention also show good insecticidal activity, part of the compounds, at very low doses, have excellent control effect on diseases caused by Plutella xylostella, armyworm, Myzus persicae, Tetranychus cinnabarinus etc.

Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor – LQFM030

Objective: The activation of the p53 pathway through the inhibition of MDM2 has been proposed as a novel therapeutic strategy against tumours. A series of cis-imidazoline analogues, termed nutlins, were reported to displace the recombinant p53 protein fro

Experimental and theoretical investigation of optical nonlinearities in (nitrovinyl)-1H-pyrazole derivative

This work reports on the optical nonlinearities of a newly synthesized pyrazole derivative, namely (E)-1-(4-chlorophenyl)-4-(2-nitrovinyl)-1H-pyrazole. The Z-scan technique with femtosecond laser pulses was used to determine the two-photon absorption (2PA

Chemoselective and regiospecific formylation of 1-phenyl-1H-pyrazoles through the duff reaction

The synthesis of formylated 1-phenyl-1H-pyrazole derivatives under the Duff reaction conditions is reported. Our results indicate that 1-phenyl-1H-pyrazole systems containing electron-withdrawing and electron-donating substituents at the phenyl moiety rea

PROTEOSTASIS REGULATORS

The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.

Complete assignment of NMR data of 22 phenyl-1H-pyrazoles' derivatives

Complete assignment of 1H and 13C NMR chemical shifts and J(1H/1H and 1H/19F) coupling constants for 22 1-phenyl-1H-pyrazoles' derivates were performed using the concerted application of 1H 1D and 1H, 13C 2D gs-HSQC and gs-HMBC experiments. All 1-phenyl-1H-pyrazoles' derivatives were synthesized as described by Finar and co-workers. The formylated 1-phenyl-1H-pyrazoles' derivatives were performed under Duff's conditions. Copyright